Project Grant RF1NS128953
- This Project Grant award of $5,949,022, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to identify novel therapeutic targets for treating cerebral amyloid angiopathy (CAA) and vascular contributions to cognitive impairment and dementia (VCID). The research, led by the Jackson Laboratory with sub-awards to Emory University, Rush...
- This Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $10,847,672 to the J. David Gladstone Institutes, a non-profit biomedical research organization, to investigate the vascular-immune mechanisms underlying cerebral amyloid angiopathy (CAA) and Alzheimer's disease pathology. The research aims to elucidate the key microglial mechanisms regulating the formation of vascular CAA versus parenchymal amyloid-beta plaques, define single-cell and...
- This Project Grant award for $2,398,590.00, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the role of brain microcirculation and capillary endothelial cell energetics in the development of vascular cognitive impairment and dementia (VCID) observed in Alzheimer's disease (AD) and AD-related dementias. The...
- This Project Grant award for $380,060 from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) supports research by the Arizona Veterans Research And Education Foundation, a non-profit organization, to evaluate anti-Medin immunotherapy for addressing vascular aging and related dementias. The project aims to develop and test the efficacy of an anti-Medin vaccine (Aim 1) as well as anti-Medin monoclonal antibodies (Aim 2) in preventing or attenuating...
- This $481,250 Project Grant was awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to Vanderbilt University Medical Center (VUMC) on September 1, 2024. The award supports the development of an innovative, non-invasive MRI imaging technique to assess membrane lipid properties in Alzheimer's disease (AD). The key objectives are to: 1) verify the relationship between the MRI nuclear Overhauser enhancement (NOE) signal and lipid properties using reconstituted phospholipid...
- This federal Project Grant award, totaling $2,683,965.00 and provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports the establishment of a human microphysiological system to elucidate cellular mechanisms underlying vulnerability to Alzheimer's disease (AD). The grant recipient, Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare...
- Federal Project Grant Summary Vasoptic Medical, Inc. received a $500,000 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded September 20, 2025, with completion targeted for September 19, 2026. The grant funds development of VasoVue NV, a non-invasive imaging platform designed to assess neurovascular dysfunction as an early-stage biomarker for Alzheimer's disease. During Phase I, Vasoptic Medical will conduct proof-of-concept research using...
- This federal Project Grant award, issued by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $4,693,249 to the University of California, Los Angeles (UCLA) to conduct research on defining the molecular spectrum of white matter vascular lesions that drive vascular cognitive impairment and dementia (VCID). The project aims to develop a better understanding of...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Massachusetts General Hospital (MGH) a Project Grant of $941,572 in May 2025 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The research will be conducted through March 31, 2030, at MGH's Research Management Division in Charlestown, Massachusetts. The project investigates the pathogenic mechanisms linking aging-related...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $149,264 Project Grant to Indiana University Indianapolis on December 5, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This research initiative, with a completion date of May 15, 2027, investigates the mechanisms by which neutrophils contribute to cognitive decline in a comorbid model of Alzheimer's Disease (AD)...
VASCULAR MECHANISMS OF DEMENTIA: CELL-TYPE SPECIFIC THERAPEUTIC AND IMAGING STRATEGIES - ABSTRACT: NEUROPATHOLOGICAL STUDIES IN DEMENTIA FREQUENTLY SHOW MIXED FEATURES INCLUDING CLASSICAL ALZHEIMER'S HALLMARKS, CEREBRAL AMYLOID ANGIOPATHY (CAA), MICROHEMORRHAGES, AND MICROINFARCTS, HIGHLIGHTING THE COMPLEXITY AND IMPORTANCE OF VASCULAR MECHANISMS IN NEURODEGENERATION. THE PRECISE MECHANISMS LEADING TO CAA, MICROVASCULAR DEGENERATION, AND DYSREGULATED CEREBRAL BLOOD FLOW (CBF) ARE POORLY UNDERSTOOD. THE CELLULAR CONSTITUENTS OF BLOOD VESSELS INCLUDE ENDOTHELIAL AND MURAL CELLS (SMOOTH MUSCLE CELLS OR PERICYTES), ALL OF WHICH HAVE CRITICAL ROLES IN CBF REGULATION AND BLOOD-BRAIN BARRIER MAINTENANCE. WHILE THESE CELLS ARE PROMINENTLY AFFECTED IN NEURODEGENERATION, THERE ARE CURRENTLY NO SPECIFIC THERAPEUTIC STRATEGIES FOR PROTECTING THEM. A KEY OBJECTIVE OF THIS APPLICATION IS TO DEVELOP INNOVATIVE STRATEGIES TO THERAPEUTICALLY TARGET AND IMAGE THE VARIOUS VASCULAR CELLULAR COMPONENTS TO IMPROVE OUR UNDERSTANDING OF MECHANISMS LEADING TO DEMENTIA. SPECIFICALLY, WE AIM TO COMPLETE PROOF-OF-CONCEPT STUDIES WITH A FOCUS ON POTENTIAL MECHANISMS OF CYTOTOXICITY MEDIATED BY IRON METABOLISM/REACTIVE OXYGEN SPECIES (ROS) THAT MAY LEAD TO MICROVASCULAR DEGENERATION. WE AIM TO DEVELOP AND TEST COMPOUNDS THAT CAN PREFERENTIALLY TARGET BRAIN PERICYTES, SMOOTH MUSCLE CELLS, AND ENDOTHELIAL CELLS WITH THE GOAL OF REDUCING INTRACELLULAR FREE IRON AND ROS TOXICITY AND AMELIORATING MICROVASCULAR DEGENERATION. THESE CELL-TYPE SPECIFIC COMPOUNDS WILL ALSO BE TESTED TO DETERMINE THEIR POTENTIAL TO BE USED AS PROBES FOR DEEP TISSUE BRAIN IMAGING IN PRECLINICAL STUDIES. TO ACHIEVE THIS, WE HAVE ASSEMBLED A MULTIDISCIPLINARY TEAM AT THE INTERFACE OF NEUROVASCULAR BIOLOGY AND CHEMISTRY AND PROPOSE A COMPREHENSIVE SET OF EXPERIMENTS THAT COMBINE INTRAVITAL BRAIN MICROSCOPY, CHEMICAL SYNTHESIS, SINGLE-CELL TRANSCRIPTOMICS, AND ANIMAL MODELS OF CAA AND MICROVASCULAR PATHOLOGY. THIS PROJECT HAS THE POTENTIAL FOR IDENTIFYING TARGETS AND STRATEGIES FOR AMELIORATING MICROVASCULAR DEGENERATION THAT COULD SIGNIFICANTLY IMPACT OUR MECHANISTIC UNDERSTANDING AND THERAPEUTIC APPROACHES FOR VASCULAR DEMENTIA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 3/9/26 | ||
| Not listed | $2.4m | 6/30/22 | ||
| Not listed | $2.4m | 6/30/22 |